Rigosertib for RDEB-SCC

Launched by PROF. JOHANN BAUER · Dec 20, 2018

Keywords

ClinConnect Summary

This clinical trial is studying a new experimental drug called rigosertib to treat a type of skin cancer known as squamous cell carcinoma (SCC) in patients with a rare skin disease called recessive dystrophic epidermolysis bullosa (RDEB). People with RDEB often develop SCC at a young age, and it can be very aggressive. The trial aims to see if rigosertib can effectively treat this cancer while being safe for patients. It will take place over about 2.5 years in two locations—London and Salzburg—with each participant being part of the study for one year.

To be eligible for this trial, participants need to be between 18 and 79 years old and have advanced SCC that has not responded to standard treatments like surgery or chemotherapy. They should not be receiving any other cancer therapies during the trial. If someone decides to join, they can expect to receive the rigosertib treatment and undergo regular check-ups to monitor their health and response to the drug. This study not only hopes to provide insights into how well rigosertib works but also aims to find out more about how it might target cancer cells specifically in patients with RDEB.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18-79 years of age;
• • 2. Diagnosis of unresectable, locally advanced or metastatic SCC confirmed prior to the Screening Visit.
• • 3. Failure to respond to RDEB SCC standard of care, such as surgical excision, radiotherapy or conventional cytotoxic chemotherapy with e.g. platin derivates (i.e.
• • cisplatin or carboplatin), 5-fluorouracil, bleomycin, methotrexate, adriamycin, taxanes, gemcitabine or ifosfamide alone or in combination or failure to respond to previous alternative biologic treatments such as epidermal growth factor inhibitors (like cetuximab and panitumumab) or immune checkpoint (programmed cell death
• • 1) inhibitors (such as nivolumab, pembrolizumab, cemiplimab). For recent guidelines on standard of care for RDEB SCC and non EB-SCC please see Mellerio et al., 2016; Stratigos et al., 2015 and Kim et al., 2018.
• • 4. Is not currently receiving any other cancer therapy.
• • 5. Measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
• • 6. Patient (or patient's legally authorized representative) must have signed an informed
• • Exclusion Criteria
• • 1. Response to standard of care.
• • 2. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure or unstable angina pectoris.
• • 3. Active systemic infection not adequately responding to appropriate therapy.
• • 4. Total bilirubin ≥ 1.5 mg/dL (≥5.3 mg/dL in patients if related to hemolysis or Gilbert's disease).
• • 5. Alanine transaminase (ALT)/aspartate transaminase (AST) ≥ 2.5 x upper limit of normal (ULN).
• • 6. Serum creatinine ≥2 .0 mg/dL or eGFR (estimated Glomerular Filtration Rate) \<60mL/min.
• • 7. White blood cell count ≤ 2000/μl, neutrophils ≤ 1500/μL, platelets ≤ 100 x103/μL, hemoglobin ≤ 7.9 g/dL.
• • 8. Known active HIV, hepatitis B or hepatitis C, where active is defined as follows: a. HIV or Hepatitis C - presence of viral load; b. Hepatitis B - antigen positive
• • 9. Uncorrected hyponatremia (defined as serum sodium value of \<125 mmol/L).
• • 10. Male patients with partners of child-bearing potential who are unwilling to use male contraception (condom) throughout the study, up to and including the 30-day nontreatment follow-up period.
• • 11. Female subjects: pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS they are willing to use one or more highly effective and reliable methods of contraception with a Pearl index ≤1 including combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral or intravaginal or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral or injectable or implantable); an intrauterine device (IUD); an intrauterine hormone-releasing system ( IUS); bilateral tubal occlusion; vasectomised partner (provided that partner is the sole sexual partner of the WOCBP trial participant and that the vasectomised partner has received medical assessment of the surgical success) or sexual abstinence (The reliability of sexuality abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject). Reliable contraception should be maintained throughout the study. A pregnancy test in serum will be performed at screening in all women of childbearing potential, and in urine at all visits. Any postmenopausal women (physiologic menopause defined as "12 consecutive months of amenorrhea") or women permanently sterilized (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) will not be required to undergo pregnancy test.
• • 12. Uncontrolled hypertension. (i.e.. systolic blood pressure greater than or equal to 140mmHg and diastolic blood pressure greater than or equal to 90mmHg despite intake of ≥ 3 antihypertensive medications with complementary mechanisms of action (a diuretic should be 1 component); (Whelton et al., 2018).
• • 13. Patient is currently participating and receiving study therapy or systemic therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
• • 14. Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.
• • 15. Patients (or parents in case of paediatric subject) unlikely to comply with the study protocol or unable to understand the nature and scope of the study or the possible benefits or unwanted effects of the study procedures and treatments.
• • 16. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
• • 17. Known hypersensitivity reaction to any of the components of study treatment.
• • 18. Presence of clinically significant ECG abnormalities based on the inverstigator´s criteria.